Trial Profile
An Open-label, Randomized, Multicenter, Phase 1b/2b Trial Investigating the Safety and Preliminary Antitumor Effects of Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Futuximab/modotuximab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Symphogen
- 23 Feb 2017 Status changed from recruiting to withdrawn prior to enrolment as Symphogen made a business decision to no longer perform the clinical study
- 15 Nov 2016 Status changed from not yet recruiting to recruiting.
- 07 Oct 2016 New trial record